A druggable targets discovery strategy for diseases (DTDS): Taking Rheumatoid arthritis as a case
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.114182 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Chaoqun Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of TCM-information Engineer of State Administration of TCM, School of Chinese Materia Medica, Beijing University of Chinese Medicine, …. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Drug Discovery, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Identifying effective druggable targets with disease-specific for diseases is a tremendous challenge in new drug development. However, current studies of druggable targets identification are most based on either druggability or disease-specific, lacking a combination of two factors. To further improve the accuracy of druggable targets discovery, a druggable target discovery strategy for diseases (DTDS) was proposed, which combined druggable targets prediction by machine learning and key targets identification by tissue-level and cellular-level transcriptomics analysis. Rheumatoid arthritis (RA), an autoimmune disease that cannot be treated entirely, was taken as a case. First, the protein-protein interaction network was constructed as the disease background network, and the classification models were established based on the topological parameters of known RA-druggable targets with druggability and non-RA targets without therapeutic effects on RA. 168 potential druggable targets were predicted by the classification models from 264 RA-related targets. Subsequently, 40 RA-specific targets were identified by tissue-level and cellular-level transcriptomics analysis from 168 potential druggable targets. Most of them were RA-druggable targets except PSMB9 and PTPRC. Finally, PSMB9 and PTPRC were further verified by in vitro experiments. The results showed that the inhibitor of PSMB9 or PTPRC could effectively inhibit inflammation and abnormal proliferation of synovial cells, proving that PSMB9 and PTPRC were potential RA-druggable targets, and further indicating that DTDS had high accuracy. In conclusion, the DTDS strategy established in this study is reliable and has been proven in identification of potential RA-druggable targets, which is expected to provide ideas and methods for systematic discovery of potential druggable targets for diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of TCM-information Engineer of State Administration of TCM, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
- Key Laboratory of TCM-information Engineer of State Administration of TCM, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China. Electronic address: zhangyanling@bucm.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, C., Zhao, S., Qiao, L., Ren, Y., Liu, K., Bi, S., Li, B., Yuan, A., Zheng, L., Wang, Z., Xu, Z., & Zhang, Y. (2025). A druggable targets discovery strategy for diseases (DTDS): Taking Rheumatoid arthritis as a case. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114182
Vancouver
Liu C, Zhao S, Qiao L, Ren Y, Liu K, Bi S, et al. A druggable targets discovery strategy for diseases (DTDS): Taking Rheumatoid arthritis as a case. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114182
BibTeX
@article{Liu2025,
author = {Liu, Chaoqun and Zhao, Shuai and Qiao, Liansheng and Ren, Yue and Liu, Kaiyang and Bi, Shijie and Li, Beiyan and Yuan, Anlei and Zheng, Lulu and Wang, Zewen and Xu, Zhenzhen and Zhang, Yanling},
title = {A druggable targets discovery strategy for diseases (DTDS): Taking Rheumatoid arthritis as a case},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.114182}
}
EUVIMED